The Global Halitosis Treatment Market is projected to grow at a CAGR of 12.8% from USD 10.75 Billion in 2022 to USD 28.53 Billion in 2030. Growing consumption of tobacco and alcohol are major factors that lead to halitosis. Chronic diseases such as failure of liver, cancer, and metabolic diseases also lead to halitosis. Gastrointestinal disease is another major factor leading to halitosis. The market experienced increased demand by a rise in initiatives taken by the governments and advancement in technology. However, a dearth in the knowledge of the diseases and its treatments is anticipated to limit the market growth.
Bronchiectasis is one of the most mentionable diseases that create halitosis and required to be treated. There is a huge of the growth seen in the mouthwash that prevents bad breath. Apart from the proper medication, mouthwash or toothpaste manufacturers have been incorporating medicaments for bad breath. CB12 is one of the most demanding medication that neutralizes the odorous sulfur from the bad breath.
The condition has several reasons, such as diet, medication, poor health hygiene, diabetes, GERD, lactose intolerance, and gum diseases. It is a major issue across the globe where a moderate case of halitosis is high, but severe cases are limited to 5% of the population. Increase in the number of people suffering from halitosis coupled with rising awareness regarding the disease and its treatment is boosting the market. In the US, approximately 80 million people spend more than USD 10.75 Billion annually on oral hygiene products.
Request a Sample@ https://qyresearchmedical.com/sample/119043
North America dominated the market for halitosis treatment. The region has high awareness regarding oral health. Prevalence of gastrointestinal disease in the region is also a major factor for halitosis among the population. Increase in the consumption of coffee, alcohol, and other sugary drinks are also propelling the growth of the market. Increase in demand for innovative medical technology is another reason why North America dominated the market.
Lungs are forecasted to hold a market share of 18% in the year 2026. Bad breath from organs is mainly due to some disease, or due to something one ate that mixes with the blood level and releases an odor.
Respiratory segment held the largest market share of 23% in the year 2018. Bronchiectasis is a long-term condition in which the airways gets wider than usual, which allow mucus to build up, thus resulting in bad breath.
Gastrointestinal is forecasted to hold a market share of 15% in the year 2026. Bad breath caused by the gut is a sign of imbalance in the digestive system.
Diagnostic Tests Outlook:
BANA test is also one of the diagnostic tests that measure the levels of a specific enzyme which is produced by bacteria caused by halitosis.
Halimeter is forecasted to have a CAGR of 12.5% during the forecast period. This diagnosis detects the low level of sulfur in the body.
In some cases, the liver is the source of halitosis. It is forecasted to have the highest CAGR of 13.9% during the forecast period. ‘Frank liver failure’ and ‘late stage liver failure’ can both lead to bad breath problem.
Asia Pacific is forecasted to have the highest CAGR of 14.0% during the forecast period. Increase in disposable income and rise in awareness among the youth is fueling the growth of the market.
Europe is forecasted to hold a market share of 28% in the year 2026. People in the region invest generously in the healthcare sector, including treatment from the dentist. The market is forecasted to grow in the future.
North America dominated with a market share of 31% in the year 2018. Awareness among people regarding the disease and availability of its treatment is driving the growth of the market.
- On the basis of Drug treatment, the market is segmented into antiseptic, antacids, ranitidine, and others.
- Antiseptic is antimicrobial and aids in reducing the possibility of sepsis, infection and other problems. It held the largest market share of 31% in the year 2018.
- The pathological segment held a market share of 53% in the year 2018. Pathological treatment includes a number of medical specialties that diagnose diseases, mostly through analysis of cell, tissue, and body fluid samples.
- Clinics are forecasted to have a higher CAGR of 13.6% during the forecast period. Regular visits to the dentist’s clinic can help restrain the problem of halitosis.
- Ranitidine is forecasted to hold a market share of 28% in the year 2026. It is commonly used to treat gastroesophageal reflux, helping with limiting bad breath.
Companies considered and profiled in this market study
Colgate-Palmolive Company, All USA Partners LLC., Dr. Harold Katz, LLC, Rowpar Pharmaceuticals, Inc., Abbott, Listerine, AstraZeneca, Oral B, Novartis, GSK, Pfizer, Philips Oral Healthcare, and Roche among others are leading players involved on the global Halitosis Treatment market.
- In October 2018, LISTERINE launched a new Oral Care category by introducing an innovative medicated product which makes the feeling of whole mouth clean on-the-go.
The Halitosis Treatment Market industry poses significant amount of opportunities for small manufacturers and startups to come up with cost-effective solutions in the manufacturing of Halitosis Treatment products. Many innovative start-ups that are growing remarkably have been profiled in the report with all their innovative techniques and developments. There is a continuous growth in demand from the end-users, which can encourage several startups to launch innovative products in this market.
Mergers and Acquisitions are an integral part of this industry. These mergers and acquisitions help us decide the strategic initiatives taken up by the leading players as well as growing companies dealing in this market, and have been included in this report.
Reports and Data forecasts in the Halitosis Treatment industry having considered the interviews with some of most the prestigious personalities and experts in this market Blood pressure monitors take up a significant amount of market shares. Bronchiectasis is one of the most mentionable diseases that create halitosis and required to be treated. There is a huge of the growth seen in the mouthwash that prevents bad breath. Apart from the proper medication mouthwash or toothpaste manufacturers have been incorporating medicaments for bad breath. CB12 is one of the most demanding medication that neutralizes the odorous sulfur from the bad breath. The main players, according to experts, need to review their strategies in order to support the following COVID 19 scenario and to maintain healthy relationships with their business partners. As a result of this pandemic, the world’s average disposable income would decrease. The main manufacturers of the company are expected to attempt to discover new areas.
Segments covered in the report
This report forecasts revenue growth at a global, regional & country level, and provides an analysis of the market trends in each of the sub-segments from 2022 to 2030. The scope of the report can be defined as:
For the purpose of this report, Reports and Data have segmented the global Halitosis Treatment Market on the basis of Type, Indication, Diagnostic Tests, Drug Treatment, End Users, and Region:
Type Outlook (Revenue: USD Billion; 2022-2030)
Indication Outlook (Revenue: USD Billion; 2022-2030)
Diagnostic Tests Outlook (Revenue: USD Billion; 2022-2030)
- Gas Chromatography
- Beta-galactosidase activity assay
Drug Treatment Outlook (Revenue: USD Billion; 2022-2030)
End Users Outlook (Revenue: USD Billion; 2022-2030)
Regional Outlook (Revenue: USD Billion; 2022-2030)
- North America
- Rest of Europe
- Asia Pacific
- Rest of APAC
- Saudi Arabia
- Rest of MEA
- Latin America
- Rest of LATAM
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119043/1500
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: